Deans' stroke musings: This is a clinical trial for Patients at risk of heart problems

Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Monday, December 12, 2016

This is a clinical trial for Patients at risk of heart problems

You had a stroke, you probably qualify.
https://antidote.me/prescreening/s/861/

This study is testing whether the drug Epanova® (omega-3 fatty acids) can help reduce the risk of serious heart problems. High triglycerides (a type of fat found in the blood), low HDL (“good”) cholesterol, and certain other factors can raise your risk of heart problems. Some patients take cholesterol-lowering drugs, called statins, however some of these patients may still be at risk. Epanova® is already FDA-approved to treat patients with severely high triglycerides, and the hope is that this drug will also be effective in patients with moderately high triglycerides.